NASDAQ: HSTOHistogen Inc Stock
$1.21-0.04 (-3.2%)
Updated Mar 31, 2023
HSTO Price
$1.21
Fair Value Price
$4.98
Market Cap
$5.17M
52 Week Low
$0.76
52 Week High
$9.40
P/E
-0.35x
P/B
0.36x
P/S
0.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.77M
Earnings
-$10.62M
Gross Margin
100%
Operating Margin
-281.77%
Profit Margin
-294.7%
Debt to Equity
0.4
Operating Cash Flow
-$10M
Beta
0.94
Next Earnings
May 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A
HSTO Overview
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HSTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSTO ($1.21) is undervalued by 75.71% relative to our estimate of its Fair Value price of $4.98 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HSTO ($1.21) is significantly undervalued by 75.71% relative to our estimate of its Fair Value price of $4.98 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HSTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HSTO due diligence checks available for Premium users.
Be the first to know about important HSTO news, forecast changes, insider trades & much more!
HSTO News
Valuation
HSTO fair value
Fair Value of HSTO stock based on Discounted Cash Flow (DCF)
Price
$1.21
Fair Value
$4.98
Undervalued by
75.71%
HSTO ($1.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HSTO ($1.21) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HSTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HSTO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
18.64x
Market
22.13x
HSTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.36x
Industry
4.98x
HSTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HSTO's financial health
Profit margin
Revenue
$4.0k
Net Income
-$3.0M
Profit Margin
-74,100%
HSTO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSTO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.1M
Liabilities
$5.7M
Debt to equity
0.4
HSTO's short-term assets ($13.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSTO's short-term assets ($13.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSTO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HSTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
-$1.0k
Financing
-$3.0k
HSTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSTO vs Biotech Stocks
Histogen Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.